27,523 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Tempus Wealth Planning LLC

Tempus Wealth Planning LLC purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 27,523 shares of the biopharmaceutical company's stock, valued at approximately $259,000.

Several other large investors have also made changes to their positions in the company. Hazlett Burt & Watson Inc. increased its holdings in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 1,569 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Amicus Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 1,884 shares during the last quarter. OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $26,000. AlphaCentric Advisors LLC lifted its stake in shares of Amicus Therapeutics by 1.2% in the third quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company's stock worth $2,189,000 after buying an additional 2,500 shares during the last quarter. Finally, Diversified Trust Co boosted its holdings in shares of Amicus Therapeutics by 3.8% during the 3rd quarter. Diversified Trust Co now owns 74,501 shares of the biopharmaceutical company's stock worth $796,000 after buying an additional 2,698 shares during the period.

Analysts Set New Price Targets

Several research analysts recently commented on FOLD shares. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Guggenheim increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.88.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded down $0.18 during trading hours on Friday, hitting $9.65. The company had a trading volume of 2,826,031 shares, compared to its average volume of 2,020,068. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of -28.38, a PEG ratio of 1.69 and a beta of 0.61. Amicus Therapeutics, Inc. has a 12 month low of $8.78 and a 12 month high of $14.03. The firm's fifty day moving average is $9.62 and its 200 day moving average is $10.45.

Insider Buying and Selling

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.20% of the stock is currently owned by corporate insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.